Legend Biotech Corp ADR
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America.
Latest LEGN News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News